Our Chief Technology Officer, Wendy Naimark, was pleased to be speaking with AbbVie Directors, Allison Hoch, PhD, MBA, Director of Global Alliances and Amy Hopkin Director of Search & Evaluation for AbbVie Eyecare, on a Harnessing Innovation & Collaboration to Accelerate Ophthalmic Drug Delivery Panel at the 4th Annual Ophthalmic Drug Delivery Summit on Thursday January 29th in San Francisco, CA.
🗣️
Topic: Unlocking Biotech-Pharma Collaboration: How Agile Small Teams & Experienced Pharma Combine Strengths to Accelerate Innovation & Deliver Real-World Impact.
Areas Covered:
✅ Co-developing platforms, managing device timelines and regulatory alignment in combo products
✅ Leveraging the speed and innovation of biotech startups with deep experience and resources of pharma
✅ Continuous learning through cooperation during diligence, development planning and execution phases
✅ The importance of proactive, transparent communication across functions to anticipate challenges and optimize for success
Address
MaRS Center, South Tower
101 College Street, Suite 300
Toronto, ON, M5G 1L7
Get in touch
(416) 673-8170
RIPPLE-ABBVIE OPHTHALMIC DRUG DELIVERY PANEL
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.
Co-Founder and Chief Technology Officer, Wendy Naimark, PhD., recently presented “Overview of the Epidel Prodrug Engineered Sustained Drug Delivery Platform” at PODD: Partnership Opportunities in Drug Delivery. Click to View
